Skip to main content

Advertisement

Fig. 5 | Journal of Neuroinflammation

Fig. 5

From: Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway

Fig. 5

Statin-Dex treatment increase the number of CD4+Foxp3+ T cells in lymphocytes. Expressions of CD4+CD25+ T cells and CD4+Foxp3+ T cells among lymph node MNC in statin-Dex group, control-Dex group, and control group were detected by FACS. The results showed that statin-Dex treatment increased the percentage of CD4+Foxp3+ T cells among lymph node MNC when compared with control-Dex and PBS treatments, while there was no difference for the percentage of CD4+CD25+ T cells. Meanwhile, we did not observe difference in the percentages of CD4+CD25+ T cells and CD4+Foxp3+ T cells between control-Dex group and control group (a, b). The results are expressed as mean ± SD (n = 5 rats per group) (*p < 0.05)

Back to article page